Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
The high immunogenicity of CT antigens and their tissue-restricted expression make them optimal targets for tumor immunotherapy and vaccine development. SSX2 is a major tumor antigen. Due to SSX2 wide expression in cancer, a single anti-SSX2 therapy will potentially benefit multiple diseases. Immunodominant SSX2-derived peptides that elicit adequate T-cell responses have been identified, and initial reports have described their successful use in vivo (Wagner et al., 2003; Ayyoub et al., 2004a; Ayyoub et al., 2004b; Neumann et al., 2004; Ayyoub et al., 2005; Kyyamova et al., 2006; Huang et al., 2007; Neumann et al., 2011; Smith and McNeel, 2011). Since the majority of tumors express more than one CT antigen, attempts at generating polyvalent T cells directed against multiple epitopes for simultaneous antigen recognition are ongoing (Gerdemann et al., 2011; Smith et al., 2011). Notably, CT antigen-specific cytotoxic T lymphocytes were able to recognize and destroy chemoresistant lymphoma cells expressing the cognate antigens (Shafer et al., 2010). Finally, CT antigen directed immunotherapy could potentially become a valuable addition to chemotherapy for effective treatment of cancer.
Josiane Eid ; Christina Garcia ; Andrea Frump
SSX2 (synovial sarcoma, X breakpoint 2)
Atlas Genet Cytogenet Oncol Haematol. 2013-05-01
Online version: http://atlasgeneticsoncology.org/gene/42406/ssx2-(synovial-sarcoma-x-breakpoint-2)
2008-04-01 SSX2 (synovial sarcoma, X breakpoint 2) by Josiane Eid,Christina Garcia,Andrea Frump